



NOV 16 2007

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bendele, et al.

Serial No.: 10/621,784

Group Art Unit No.: 1649

Filed: July 16, 2003

Examiner: Christina Borgeest

For: USE OF IL-1 INHIBITORS FOR TREATING IL-1 MEDIATED DISEASES

Docket No.: A-398G

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Responsive to the Restriction Requirement mailed June 13, 2006, Applicants elect, without traverse, species I-a, IL-1Ra, encompassed in claims 27 to 31. In addition, Applicants acknowledge that upon allowance of a generic claim, for example upon allowance of claim 27, Applicants will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of the allowable generic claim as provided by 37 CFR § 1.141.

The Examiner in charge of this application is invited to contact the undersigned representative as indicated below if doing so is believed to be helpful.

Respectfully submitted,

Randolph N. Mohr
 Attorney for Applicants
 Registration No.: 45,590
 Phone: (805) 447-8949
 Date: November 16, 2007

Please send all future correspondence to:

US Patent Operations/ MKH
 Dept. 4300, M/S 28-2-C
 AMGEN INC.
 One Amgen Center Drive
 Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE"Express Mail" mail labeling number: EL 732698525 USDate of Deposit: November 16, 2007

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Karen Podgorny

Printed Name

Signature